Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Nanotechnology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder impacting cognitive functions.
• Current treatments involve drugs like Donepezil HCl and Memantine HCl, often with systemic side effects.
• Nanostructured Lipid Carriers (NLCs) offer a promising approach to improve drug circulation and minimize side effects.

Purpose of the Study:

• To optimize Nanostructured Lipid Carriers (NLCs) for transdermal delivery of Donepezil HCl and Memantine HCl.
• To utilize data mining tools, including Artificial Neural Network (ANN) and Box-Behnken Design (BBD), for formulation optimization.
• To enhance neuroprotection and manage dementia symptoms through improved drug delivery.

Main Methods:

• NLCs were formulated using high-speed homogenization and ultrasonication.
• Box-Behnken Design (BBD) and Artificial Neural Network (ANN) were employed for optimization.
• Key variables included lipid ratios, surfactant concentration, and homogenizer speed (RPM).

Main Results:

• Formulated NLCs exhibited particle sizes between 67.0±0.45 to 142.4±0.52 nm.
• Encapsulation efficiency (%EE) for both drugs exceeded 75%, with a Zeta potential of -26±0.36 mV.
• Permeation studies indicated prolonged drug release, suggesting enhanced skin penetration.

Conclusions:

• NLCs are a viable carrier system for transdermal drug delivery, facilitating deeper skin penetration and systemic circulation.
• This formulation holds significant potential for the effective management of dementia associated with Alzheimer's disease.
• ANN and BBD are effective data mining tools for systematic NLC formulation development and optimization.